金城医药(300233) - 2025 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2025 was ¥721,919,205.16, a decrease of 22.52% compared to ¥931,696,552.76 in the same period last year[5]. - Net profit attributable to shareholders was ¥35,054,760.33, down 57.75% from ¥82,971,349.76 year-on-year[5]. - Basic earnings per share decreased by 59.09% to ¥0.09 from ¥0.22 in the same period last year[5]. - Net profit for the current period is ¥36,298,903.66, a decline of 59.3% compared to ¥89,158,928.05 in the previous period[23]. - Basic and diluted earnings per share are both ¥0.09, down from ¥0.22 in the previous period[24]. Cash Flow - The net cash flow from operating activities was -¥8,565,391.95, a decline of 120.70% compared to ¥41,373,196.64 in the previous year[5]. - Cash flow from operating activities shows a net outflow of ¥8,565,391.95, compared to a net inflow of ¥41,373,196.64 in the previous period[25]. - The net cash flow from financing activities was -¥65,461,298.33, a decline of 354.21% compared to a net inflow of ¥25,751,266.86 in the previous year[14]. - Cash and cash equivalents decreased to ¥853,676,725.38 from ¥917,670,953.09[17]. - Cash and cash equivalents at the end of the period amount to ¥796,398,844.56, down from ¥921,001,178.30 at the end of the previous period[26]. Assets and Liabilities - Total assets at the end of the reporting period were ¥5,471,384,233.67, down 2.38% from ¥5,604,990,741.71 at the end of the previous year[5]. - Total current assets amount to ¥2,184,257,009.16, a decrease from ¥2,258,285,131.73 at the beginning of the period[18]. - Total liabilities decreased to ¥1,657,956,535.57 from ¥1,772,836,587.70[19]. - Total assets and equity decreased to ¥5,471,384,233.67 and ¥3,813,427,698.10 respectively, from ¥5,604,990,741.71 and ¥3,832,154,154.01 in the previous period[20]. - The company has a total equity of ¥3,813,427,698.10, unchanged from the previous period[19]. Operational Metrics - The decline in revenue was primarily due to a decrease in the prices of pharmaceutical intermediates and the impact of national centralized procurement on sales volume and prices of certain products[9]. - Sales expenses decreased by 56.48% to ¥74,794,902.94, attributed to reduced market promotion activities due to centralized procurement[13]. - Total operating costs for the current period are ¥682,091,200.85, down 17.3% from ¥824,597,996.18 in the previous period[21]. - The company reported a significant increase in accounts receivable by 144.70% to ¥51,960,111.27 due to increased issuance of pledged notes[12]. - The company experienced a significant increase in credit impairment losses, totaling ¥7,015,544.06, compared to ¥2,270,345.38 in the previous period[23]. Shareholder Information - Total number of common shareholders at the end of the reporting period is 33,604[16]. - The largest shareholder, Zibo Jincheng Industrial Investment Co., Ltd., holds 20.46% of shares, totaling 78,552,154 shares, with 17,588,900 shares pledged[16]. Inventory and Expenditures - The company’s inventory stands at ¥596,359,058.41, slightly down from ¥598,863,558.41[17]. - The company has ongoing development expenditures of ¥252,798,405.62, up from ¥240,729,227.18[18]. Future Outlook - The company plans to implement new accounting standards starting from 2025, which may impact future financial reporting[27].